Floatz logo

Volitinib

Papillary Renal Cell Carcinoma

AstraZenecaSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

21 Active assets in the Papillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
First Affiliated Hospital, Sun Yat-Sen University
Phase 3BB
Pembrolizumab
First Affiliated Hospital, Sun Yat-Sen University
Phase 3BB
Cabozantinib
National Cancer Institute (NCI)
Phase 2BB
Durvalumab
AstraZeneca
Phase 3B

View all 35 →

Same molecule, other indications

Volitinib is also rated in:

non-small cell lung carcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →
renal cell carcinomaActive
BB
Indicative · Phase 3
64 / 100
View asset →
hepatocellular carcinomaActive
B
Indicative · Phase 3
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →